ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

DOW JONES NEWSWIRES Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations. The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline. Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion. Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion. Operating margin rose to 36.4% from 34.9%. Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion. The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million. Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Amgen Inc. (AMGN)
11/25/201509:04:03Johnson & Johnson's Latest FDA Approval Could Spell Problems...
11/24/201508:38:03Healthcare's Greatest Dividend Stocks
11/24/201502:00:00European Commission Approves Amgen's BLINCYTO® (blinatumomab...
11/23/201508:50:00CVS Chooses New Cholesterol Drug for Caremark
11/23/201508:29:00CVS Chooses Repatha as New Cholesterol Drug for Caremark
11/23/201508:10:00Amgen Announces Repatha® Preferred Position On CVS Health Commercial...
11/21/201508:00:155 Things Amgen, Inc. Wants You to Know
11/20/201518:08:02The Best Healthcare ETF of the Week
11/20/201517:44:03Better Dividend Stock: Amgen or AstraZeneca PLC?
11/19/201516:00:00European Commission Approves Kyprolis® (carfilzomib) For Combination...
11/19/201510:03:08Amgen's Repatha Is Too Bloody Pricey for the U.K.
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/16/201516:00:00Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at t...
11/14/201507:21:02These 2 Companies Could Revolutionize Heart Disease Prevention
11/13/201512:02:03A Bounty of Data Pushes Amgen Higher by 14% in October
11/12/201516:46:32Statement of Changes in Beneficial Ownership (4)
11/12/201506:58:034 Observations You May Have Overlooked in Celgene's Q3 Earnings...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations